AstraZeneca trials show antibody drug more than 80% effective at preventing COVID-19
infectious-disease infectious-disease AstraZeneca announced Thursday that its healthy-living is more than 80% effective at reducing risk of severe infectious-disease” target=”_blank”>disease< Analysis of the ongoing Provent trial with a six-month follow-up found that one 300- mg intramuscular dose of AZD7442 reduced the risk of developing symptomatic COVID-19 compared to placebo by 83%. “The AZD7442 PROVENT trial…